


REMARKS

Favorable reconsideration of this application is requested in view of the above amendments and the following remarks. Claim 1 has been amended. The amendment to claim 1 is supported by the original disclosure, for example by page 44, lines 12-24 of the specification. Claims 1-19, 24-26 and 30 are pending.

Claim Rejections – 35 USC § 102

Claims 1-15, 17, 19 and 30 are rejected under 35 USC 102(e) as being anticipated by Dolle et al. (US Publication No. 2005/01007355, now US Patent No. 7,160,902). Applicants respectfully traverse the rejection.


Compound 36 of Dolle has the following structure:




Compound 36 corresponds to ring B in the Formula (1) being a pyrrolidine ring. On the other hand, claim 1 recites that ring B is a piperazine ring which may be substituted, an imidazoline ring which may be substituted, an imidazole ring which may be substituted, a thiazoline ring which may be substituted, or a fused nitrogen-containing heterocyclic ring which may be substituted. Accordingly, Dolle does not anticipate claims 1-15, 17, 19 and 30.

Claim Rejections – 35 USC § 112

Claim 1 is rejected under 35 USC 112, first paragraph, as failing to comply with the written description requirement. The rejection is rendered moot, as the excluded two species



and




have been removed. Applicants do not concede the correctness of the rejection.

Claim Objections

Claims 2-17, 19 and 30 are objected to for depending on rejected claim 1. Applicants submit that the rejections to claim 1 should be withdrawn in view of the discussions above. Therefore, the objection to claims 2-17, 19 and 30 should be withdrawn.

In view of the above, favorable reconsideration in the form of a notice of allowance is courteously requested. The Examiner is invited to contact the undersigned at 612.455.3804 if there are any remaining issues.



Respectfully submitted,

HAMRE, SCHUMANN, MUELLER &
LARSON, P.C.
P.O. Box 2902
Minneapolis, MN 55402-0902
(612) 455-3800

Dated: 13 July 2009

By:

Douglas P. Mueller
Reg. No. 30,300

DPM/ym